Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.

Correa AF, Jegede O, Haas NB, Flaherty KT, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG.

J Clin Oncol. 2019 Jun 19:JCO1900107. doi: 10.1200/JCO.19.00107. [Epub ahead of print]

PMID:
31216227
2.

Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805).

Stein MN, Chen YH, Carducci MA, Hudes GR, Lerma PM, Tan WW, Dalune R, Rowland KM, Kuzel TM, DiPaola RS.

Am J Clin Oncol. 2019 Apr;42(4):375-381. doi: 10.1097/COC.0000000000000526.

PMID:
30789412
3.

Correlation of Prostate Cancer CHD1 Status with Response to Androgen Deprivation Therapy: a Pilot Study.

Tabakin AL, Sadimin ET, Tereshchenko I, Kareddula A, Stein MN, Mayer T, Hirshfield KM, Kim IY, Tischfield J, DiPaola RS, Singer EA.

J Genitourin Disord. 2018;2(1). pii: 1006. Epub 2018 Jul 31.

4.

Association between age and sex and mortality after adjuvant therapy for renal cancer.

Mamtani R, Wang XV, Gyawali B, DiPaola RS, Epperson CN, Haas NB, Dutcher JP.

Cancer. 2019 May 15;125(10):1637-1644. doi: 10.1002/cncr.31955. Epub 2019 Jan 8.

PMID:
30620389
5.

New developments in mechanisms of prostate cancer progression.

Howard N, Clementino M, Kim D, Wang L, Verma A, Shi X, Zhang Z, DiPaola RS.

Semin Cancer Biol. 2018 Sep 10. pii: S1044-579X(18)30079-8. doi: 10.1016/j.semcancer.2018.09.003. [Epub ahead of print] Review.

PMID:
30213689
6.
7.

Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.

Buti S, Puligandla M, Bersanelli M, DiPaola RS, Manola J, Taguchi S, Haas NB.

Ann Oncol. 2018 Jul 1;29(7):1604. doi: 10.1093/annonc/mdx799. No abstract available.

PMID:
29608641
8.

Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.

Morgans AK, Chen YH, Sweeney CJ, Jarrard DF, Plimack ER, Gartrell BA, Carducci MA, Hussain M, Garcia JA, Cella D, DiPaola RS, Patrick-Miller LJ.

J Clin Oncol. 2018 Apr 10;36(11):1088-1095. doi: 10.1200/JCO.2017.75.3335. Epub 2018 Mar 9.

9.

Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805.

Estabrook R, Cella D, Zhao F, Manola J, DiPaola RS, Wagner LI, Haas NB.

Qual Life Res. 2018 Jun;27(6):1589-1597. doi: 10.1007/s11136-018-1817-4. Epub 2018 Mar 5.

10.

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ.

J Clin Oncol. 2018 Apr 10;36(11):1080-1087. doi: 10.1200/JCO.2017.75.3657. Epub 2018 Jan 31.

11.

p62 as a therapeutic target for inhibition of autophagy in prostate cancer.

Wang L, Kim D, Wise JTF, Shi X, Zhang Z, DiPaola RS.

Prostate. 2018 Apr;78(5):390-400. doi: 10.1002/pros.23483. Epub 2018 Jan 25.

PMID:
29368435
12.

Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial.

Zhao F, Cella D, Manola J, DiPaola RS, Wagner LI, Haas NSB.

Support Care Cancer. 2018 Jun;26(6):1889-1895. doi: 10.1007/s00520-017-4027-7. Epub 2017 Dec 23.

13.

Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.

Jilaveanu LB, Puligandla M, Weiss SA, Wang XV, Zito C, Flaherty KT, Boeke M, Neumeister V, Camp RL, Adeniran A, Pins M, Manola J, DiPaola RS, Haas NB, Kluger HM.

Clin Cancer Res. 2018 Jan 1;24(1):217-223. doi: 10.1158/1078-0432.CCR-17-1555. Epub 2017 Oct 24.

14.

Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.

Buti S, Puligandla M, Bersanelli M, DiPaola RS, Manola J, Taguchi S, Haas NB.

Ann Oncol. 2017 Nov 1;28(11):2747-2753. doi: 10.1093/annonc/mdx492.

15.

Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.

Ristau BT, Manola J, Haas NB, Heng DYC, Messing EM, Wood CG, Kane CJ, DiPaola RS, Uzzo RG.

J Urol. 2018 Jan;199(1):53-59. doi: 10.1016/j.juro.2017.07.042. Epub 2017 Jul 18.

16.

A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805]).

Pili R, Jegede O, Carducci MA, Manola J, Groteluschen DL, Appleman LL, Liu G, Shanks JC, Dakhil SR, Dutcher J, DiPaola RS.

Clin Genitourin Cancer. 2017 Dec;15(6):642-651.e1. doi: 10.1016/j.clgc.2017.04.023. Epub 2017 Apr 26.

17.

Roadmap to a Comprehensive Clinical Data Warehouse for Precision Medicine Applications in Oncology.

Foran DJ, Chen W, Chu H, Sadimin E, Loh D, Riedlinger G, Goodell LA, Ganesan S, Hirshfield K, Rodriguez L, DiPaola RS.

Cancer Inform. 2017 Mar 2;16:1176935117694349. doi: 10.1177/1176935117694349. eCollection 2017.

18.

First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.

Stein MN, Bertino JR, Kaufman HL, Mayer T, Moss R, Silk A, Chan N, Malhotra J, Rodriguez L, Aisner J, Aiken RD, Haffty BG, DiPaola RS, Saunders T, Zloza A, Damare S, Beckett Y, Yu B, Najmi S, Gabel C, Dickerson S, Zheng L, El-Deiry WS, Allen JE, Stogniew M, Oster W, Mehnert JM.

Clin Cancer Res. 2017 Aug 1;23(15):4163-4169. doi: 10.1158/1078-0432.CCR-16-2658. Epub 2017 Mar 22.

19.

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.

Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK.

JAMA Oncol. 2017 Sep 1;3(9):1249-1252. doi: 10.1001/jamaoncol.2017.0076.

20.

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.

Hirshfield KM, Tolkunov D, Zhong H, Ali SM, Stein MN, Murphy S, Vig H, Vazquez A, Glod J, Moss RA, Belyi V, Chan CS, Chen S, Goodell L, Foran D, Yelensky R, Palma NA, Sun JX, Miller VA, Stephens PJ, Ross JS, Kaufman H, Poplin E, Mehnert J, Tan AR, Bertino JR, Aisner J, DiPaola RS, Rodriguez-Rodriguez L, Ganesan S.

Oncologist. 2016 Nov;21(11):1315-1325. doi: 10.1634/theoncologist.2016-0049. Epub 2016 Aug 26.

21.

Precision Medicine: Implications for Science and Practice.

Ganesan S, Rodriguez-Rodriguez L, DiPaola RS.

J Am Coll Surg. 2016 Sep;223(3):433-439.e1. doi: 10.1016/j.jamcollsurg.2016.05.020. Epub 2016 Jun 16. No abstract available.

PMID:
27321387
22.

BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer.

Bansal N, Bartucci M, Yusuff S, Davis S, Flaherty K, Huselid E, Patrizii M, Jones D, Cao L, Sydorenko N, Moon YC, Zhong H, Medina DJ, Kerrigan J, Stein MN, Kim IY, Davis TW, DiPaola RS, Bertino JR, Sabaawy HE.

Clin Cancer Res. 2016 Dec 15;22(24):6176-6191. doi: 10.1158/1078-0432.CCR-15-3107. Epub 2016 Jun 15.

23.

Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.

Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez-Rodriquez L, Kaufman HL, Ali S, Ross JS, Pavlick DC, Bhanot G, White EP, DiPaola RS, Lovell A, Cheng J, Ganesan S.

J Clin Invest. 2016 Jun 1;126(6):2334-40. doi: 10.1172/JCI84940. Epub 2016 May 9.

24.

Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.

Rodriguez-Rodriguez L, Hirshfield KM, Rojas V, DiPaola RS, Gibbon D, Hellmann M, Isani S, Leiser A, Riedlinger GM, Wagreich A, Ali SM, Elvin JA, Miller VA, Ganesan S.

Gynecol Oncol. 2016 Apr;141(1):2-9. doi: 10.1016/j.ygyno.2016.02.021.

25.

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS.

Lancet. 2016 May 14;387(10032):2008-16. doi: 10.1016/S0140-6736(16)00559-6. Epub 2016 Mar 9. Erratum in: Lancet. 2016 May 14;387(10032):1998.

26.

Atg7 cooperates with Pten loss to drive prostate cancer tumor growth.

Santanam U, Banach-Petrosky W, Abate-Shen C, Shen MM, White E, DiPaola RS.

Genes Dev. 2016 Feb 15;30(4):399-407. doi: 10.1101/gad.274134.115.

27.

A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.

Stein MN, Hussain M, Stadler WM, Liu G, Tereshchenko IV, Goodin S, Jeyamohan C, Kaufman HL, Mehnert J, DiPaola RS.

Clin Genitourin Cancer. 2016 Feb;14(1):22-7. doi: 10.1016/j.clgc.2015.09.010. Epub 2015 Sep 21.

28.

Transcriptomic analysis of pancreatic cancer cells in response to metformin and aspirin: an implication of synergy.

Yue W, Wang T, Zachariah E, Lin Y, Yang CS, Xu Q, DiPaola RS, Tan XL.

Sci Rep. 2015 Aug 21;5:13390. doi: 10.1038/srep13390.

29.

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS.

N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5.

30.

Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809).

McNeel DG, Chen YH, Gulley JL, Dwyer AJ, Madan RA, Carducci MA, DiPaola RS.

Hum Vaccin Immunother. 2015;11(10):2469-74. doi: 10.1080/21645515.2015.1062190.

31.

Primary radiotherapy vs conservative management for localized prostate cancer--a population-based study.

Lu-Yao GL, Kim S, Moore DF, Shih W, Lin Y, DiPaola RS, Shen S, Zietman A, Yao SL.

Prostate Cancer Prostatic Dis. 2015 Dec;18(4):317-24. doi: 10.1038/pcan.2015.30. Epub 2015 Jun 23.

32.
33.

Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2.

Yue W, Zheng X, Lin Y, Yang CS, Xu Q, Carpizo D, Huang H, DiPaola RS, Tan XL.

Oncotarget. 2015 Aug 28;6(25):21208-24.

34.

Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.

Bansal N, Mishra PJ, Stein M, DiPaola RS, Bertino JR.

Oncotarget. 2015 Jun 20;6(17):15321-31.

35.

Clinical research in metastatic prostate cancer: a focus on impact and value.

Hussain M, DiPaola RS.

Am Soc Clin Oncol Educ Book. 2015:17-21. doi: 10.14694/EdBook_AM.2015.35.17. Review. No abstract available.

36.

Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.

Haas NB, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane CJ, Jewett M, Wood L, Wood CG, Atkins MB, Dutcher JJ, Wilding G, DiPaola RS.

Clin Cancer Res. 2015 Sep 15;21(18):4048-54. doi: 10.1158/1078-0432.CCR-15-0215. Epub 2015 May 12.

37.

Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Lin Y, DiPaola RS, Yao SL.

Eur Urol. 2015 Nov;68(5):805-11. doi: 10.1016/j.eururo.2015.03.021. Epub 2015 Mar 21.

38.

Next generation sequencing as an aid to diagnosis and treatment of an unusual pediatric brain cancer.

Glod J, Song M, Sharma A, Tyagi R, Rhodes RH, Weissmann DJ, Roychowdhury S, Khan A, Kane MP, Hirshfield K, Ganesan S, DiPaola RS, Rodriguez-Rodriguez L.

J Pers Med. 2014 Jul 15;4(3):402-11. doi: 10.3390/jpm4030402.

39.

A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.

DiPaola RS, Chen YH, Bubley GJ, Stein MN, Hahn NM, Carducci MA, Lattime EC, Gulley JL, Arlen PM, Butterfield LH, Wilding G.

Eur Urol. 2015 Sep;68(3):365-71. doi: 10.1016/j.eururo.2014.12.010. Epub 2014 Dec 18.

40.

Potent inhibitory effect of δ-tocopherol on prostate cancer cells cultured in vitro and grown as xenograft tumors in vivo.

Huang H, He Y, Cui XX, Goodin S, Wang H, Du ZY, Li D, Zhang K, Tony Kong AN, DiPaola RS, Yang CS, Conney AH, Zheng X.

J Agric Food Chem. 2014 Nov 5;62(44):10752-8. doi: 10.1021/jf504058f. Epub 2014 Oct 27.

41.

Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer.

Song M, DiPaola RS, Cracchiolo BM, Gibbon DG, Hellmann M, Nieves-Neira W, Vaidya A, Wagreich AR, Shih WJ, Rodriguez-Rodriguez L.

Int J Gynecol Cancer. 2014 Nov;24(9):1636-41. doi: 10.1097/IGC.0000000000000258.

42.

ERG and CHD1 heterogeneity in prostate cancer: use of confocal microscopy in assessment of microscopic foci.

Tereshchenko IV, Zhong H, Chekmareva MA, Kane-Goldsmith N, Santanam U, Petrosky W, Stein MN, Ganesan S, Singer EA, Moore D, Tischfield JA, DiPaola RS.

Prostate. 2014 Nov;74(15):1551-9. doi: 10.1002/pros.22873. Epub 2014 Aug 29.

43.

Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL.

JAMA Intern Med. 2014 Sep;174(9):1460-7. doi: 10.1001/jamainternmed.2014.3028.

44.

Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo.

Huang H, Cui XX, Chen S, Goodin S, Liu Y, He Y, Li D, Wang H, Van Doren J, Dipaola RS, Conney AH, Zheng X.

Anticancer Res. 2014 Jul;34(7):3357-63.

45.

Comparative effects of two different forms of selenium on oxidative stress biomarkers in healthy men: a randomized clinical trial.

Richie JP Jr, Das A, Calcagnotto AM, Sinha R, Neidig W, Liao J, Lengerich EJ, Berg A, Hartman TJ, Ciccarella A, Baker A, Kaag MG, Goodin S, DiPaola RS, El-Bayoumy K.

Cancer Prev Res (Phila). 2014 Aug;7(8):796-804. doi: 10.1158/1940-6207.CAPR-14-0042. Epub 2014 Jun 17.

46.

Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501).

Pillai RN, Aisner J, Dahlberg SE, Rogers JS, DiPaola RS, Aisner S, Ramalingam SS, Schiller JH.

Cancer Chemother Pharmacol. 2014 Jul;74(1):177-83. doi: 10.1007/s00280-014-2427-7. Epub 2014 May 24.

47.

An active learning approach for rapid characterization of endothelial cells in human tumors.

Padmanabhan RK, Somasundar VH, Griffith SD, Zhu J, Samoyedny D, Tan KS, Hu J, Liao X, Carin L, Yoon SS, Flaherty KT, Dipaola RS, Heitjan DF, Lal P, Feldman MD, Roysam B, Lee WM.

PLoS One. 2014 Mar 6;9(3):e90495. doi: 10.1371/journal.pone.0090495. eCollection 2014.

48.

Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment.

Yue W, Yang CS, DiPaola RS, Tan XL.

Cancer Prev Res (Phila). 2014 Apr;7(4):388-97. doi: 10.1158/1940-6207.CAPR-13-0337. Epub 2014 Feb 11. Review.

49.

Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib.

Wang H, Cui XX, Goodin S, Ding N, Van Doren J, Du Z, Huang MT, Liu Y, Cheng X, Dipaola RS, Conney AH, Zheng X.

Oncol Rep. 2014 Feb;31(2):835-41. doi: 10.3892/or.2013.2885. Epub 2013 Nov 29.

50.

Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells.

Tedeschi PM, Markert EK, Gounder M, Lin H, Dvorzhinski D, Dolfi SC, Chan LL, Qiu J, DiPaola RS, Hirshfield KM, Boros LG, Bertino JR, Oltvai ZN, Vazquez A.

Cell Death Dis. 2013 Oct 24;4:e877. doi: 10.1038/cddis.2013.393.

Supplemental Content

Loading ...
Support Center